Video Shorts

1:05
Outlining Questions About the Future of HR+ Breast Cancer Care
27 minutes ago
by
Adam M. Brufsky, MD, PhD

1:06
Defining the Importance of Real-World Data in Lung Cancer
4 hours ago
by
William Phillips, MD

1:16
The Rationale to Wait for Radiographic Progression Before Switching Breast Cancer Therapy
a day ago
by
Kelsey Natsuhara, MD

0:50
Examining the Cardiovascular Risks of Hormone Therapy in Prostate Cancer
a day ago
by
Sagar Patel, MD

1:44
The Importance of Giving the Most Effective Therapy Upfront in TNBC
2 days ago
by
Kevin Punie, MD, PhD

1:12
Explaining ctDNA Analysis Findings From SERENA-6 in Breast Cancer
2 days ago
by
Sara A. Hurvitz, MD, FACP

1:07
Targeting FcRH5 in Multiple Myeloma
2 days ago
by
Adam D. Cohen, MD

0:37
Why Early CAR T-Cell Therapy Is a Game-Changer in Myeloma
7 days ago
by
Hamza Hashmi, MD

0:44
Exploring the Future of Radiopharmaceuticals in Prostate Cancer
7 days ago
by
Jeff Michalski, MD, MBA, FASTRO

0:34
Exploring Brenetafusp in Melanoma
8 days ago
by
Diwakar Davar, MD

1:52
Exploring the Next Steps for Belzutifan in RCC
9 days ago
by
Toni Choueiri, MD

0:41
Discussing the Safety of Silicone Breast Implants
12 days ago
by
Maelee Yang, MD

1:37
Which Lung Cancer Experts Changed Your Mind at 2026 BTG Lung?
13 days ago
by
Caroline Seymour(+1 more)

1:18
The Potential Effect of Daraxonrasib for Pancreatic Cancer Management
13 days ago
by
Shubham Pant, MD, MBBS

1:31
Examining a Novel Vaccine in Pancreatic Cancer
14 days ago
by
Elizabeth Jaffee, MD

1:52
Discussing the Biggest Unmet Needs to be Addressed at 2026 BTG Lung
14 days ago
by
Caroline Seymour(+1 more)

2:02
ATLG vs PTCy as GVHD Prophylaxis in Hematologic Malignancies
15 days ago
by
Johannes Schetelig, MD, MSc

1:03
Outlining the Rationale for an ASCENT-07 Subgroup Analysis in Breast Cancer
16 days ago
by
Yeon Hee Park, MD

1:02
Spotlighting the FDA Approval of Palbociclib Plus Trastuzumab for HER2+ Breast Cancer
16 days ago
by
Shimoli Barot, MD

1:16
Exploring the Potential Role of Cancer Vaccines in Pancreatic Cancer
16 days ago
by
Elizabeth Jaffee, MD

1:35
Breaking Down Zanubrutinib Plus Sonrotoclax in MCL and Next Steps for the Combination
19 days ago
by
Marc S. Hoffmann, MD

0:22
Explaining the Significance of the FDA Approval of Pembro Plus EV in MIBC
19 days ago
by
Matthew D. Galsky, MD

0:42
Targeting PRAME in Melanoma
20 days ago
by
Diwakar Davar, MD

1:10
Would You Rather? With Two Onc Docs!
20 days ago
by
Samantha A. Armstrong, MD(+2 more)

0:51
Explaining the Rationale for the OPTIMA Trial in Early Breast Cancer
21 days ago
by
Robert Stein, MBBS, PhD

1:09
Highlighting the Importance of Innovative Glioblastoma Research
21 days ago
by
Peter E. Fecci, MD, PhD

1:33
Unpacking Patient-Reported Outcomes in IMvigor011
21 days ago
by
Joaquim Bellmunt, MD, PhD

0:21
Explaining the Next Steps for Studying Ipatasertib Plus Pembrolizumab in HNSCC
22 days ago
by
Jacob Stephen Thomas, MD

0:43
Important Expectations With Later Lines of Therapy in Older Patients with CLL
22 days ago
by
Daniel A. Ermann, MD

1:11
Exploring HSV-Based Immunotherapy in Advanced NSCLC
23 days ago
by
Wen Wee Ma, MBBS
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Rituximab Biosimilar for Hematologic Malignancies
2
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
3
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
4
Emerging Maintenance Strategies May be the Key to Extending Survival in ES-SCLC
5
